2023
DOI: 10.1111/cbdd.14399
|View full text |Cite
|
Sign up to set email alerts
|

Dihydropyrimidine derivatives as MDM2 inhibitors

Ali Mehri,
Karim Mahnam,
Hajar Sirous
et al.

Abstract: One of the chief pathways to regulate p53 levels is MDM2 protein, which negatively controls p53 by direct inhibition. Many cancers overproduce MDM2 protein to interrupt p53 functions. Therefore, impeding MDM2's binding to p53 can reactivate p53 in tumor cells may suggest an effective approach for tumor therapy. Here, some Monastrol derivatives were designed in silico as MDM2 inhibitors, and their initial cytotoxicity was evaluated in vitro on MFC‐7 and MDA‐MB‐231 cells. A small library of Monastrol derivatives… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 56 publications
(66 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?